Janus Henderson Group
AVDL

Janus Henderson Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Janus Henderson Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,823,865
Closed -$39.3M – 2413
2025
Q4 		$39.3M Sell
1,823,865
-5,605,853
-75% -$109M 0.02% 458
2025
Q3 		$113M Sell
7,429,718
-3,702,413
-33% -$48.2M 0.05% 259
2025
Q2 		$98.5M Sell
11,132,131
-2,460,203
-18% -$21.6M 0.05% 263
2025
Q1 		$109M Sell
13,592,334
-487,885
-3% -$4.09M 0.06% 255
2024
Q4 		$148M Buy
14,080,219
+753,332
+6% +$9.15M 0.08% 228
2024
Q3 		$175M Buy
13,326,887
+29,570
+0.2% +$450K 0.09% 201
2024
Q2 		$187M Buy
13,297,317
+382,157
+3% +$6.23M 0.1% 179
2024
Q1 		$218M Buy
12,915,160
+1,789,830
+16% +$26.7M 0.12% 178
2023
Q4 		$157M Buy
11,125,330
+487,023
+5% +$5.72M 0.09% 207
2023
Q3 		$110M Buy
10,638,307
+3,115,762
+41% +$41.7M 0.07% 236
2023
Q2 		$124M Buy
7,522,545
+695,758
+10% +$9.04M 0.08% 223
2023
Q1 		$62.5M Buy
6,826,787
+5,619,257
+465% +$46.2M 0.04% 331
2022
Q4 		$8.63M Buy
+1,207,530
New +$8.47M 0.01% 753
2022
Q2 		– Sell
-1,410,387
Closed -$9.63M – 2599
2022
Q1 		$9.63M Buy
1,410,387
+407,069
+41% +$2.8M ﹤0.01% 896
2021
Q4 		$8.12M Buy
1,003,318
+192,061
+24% +$1.76M ﹤0.01% 946
2021
Q3 		$7.94M Buy
811,257
+68,485
+9% +$539K ﹤0.01% 950
2021
Q2 		$5M Buy
742,772
+489,545
+193% +$3.89M ﹤0.01% 1058
2021
Q1 		$2.3M Buy
253,227
+23,825
+10% +$193K ﹤0.01% 1158
2020
Q4 		$1.54M Buy
+229,402
New +$1.43M ﹤0.01% 1162
2017
Q4 		– Sell
-2,154,082
Closed -$22.6M – 1308
2017
Q3 		$22.6M Sell
2,154,082
-30,829
-1% -$294K 0.01% 709
2017
Q2 		$24.1M Buy
+2,184,911
New +$21.9M 0.02% 697

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Janus Henderson Group's AVDL Position: Q1 2026 in Review

Janus Henderson Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,823,865 shares — an estimated $39.3M sold.

Janus Henderson Group first reported a position in AVDL in Q2 2017 and held it in 21 quarters. The position peaked at $218M in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Janus Henderson Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Janus Henderson Group sold 1,823,865 Avadel Pharmaceuticals shares in Q1 2026, an estimated $39.3M.
  • Janus Henderson Group first reported a position in Avadel Pharmaceuticals in Q2 2017 and held it in 21 quarters.
  • Janus Henderson Group's Avadel Pharmaceuticals position peaked at $218M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.